Bristol Myers Squibb (BMY) announces positive topline results from phase 3 SCOUT-HCM trials evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy

Bristol Myers Squibb's announcement of positive topline results from its phase 3 SCOUT-HCM trials for Camzyos in adolescents is a strong signal for the company's R&D success and future revenue potential in the cardiology space.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

AbbVie (ABBV) and Remegen announce exclusive licensing agreement to develop a novel bispecific antibody for advanced solid tumours

EU Commissioner says it would be the end of NATO if the US took Greenland by force

Bristol Myers Squibb (BMY) announces positive topline results from phase 3 SCOUT-HCM trials evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy

Boston Scientific (BSX) announces an agreement to acquire Valencia Technologies Corporation; exp. to complete in H1'26 and have an immaterial impact to Adj. EPS

Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This news could bolster investor confidence and may attract attention from analysts looking for growth stories in the biotech sector, especially if the drug addresses a significant unmet medical need. Overall, this development likely enhances BMY's market positioning and could impact stock performance positively.

Related headlines

The whole workspace, free to try.

Try it free